Study of SPG302 in Healthy Volunteers and ALS Participants (NCT05882695) | Clinical Trial Compass
CompletedPhase 1
Study of SPG302 in Healthy Volunteers and ALS Participants
Australia88 participantsStarted 2023-07-03
Plain-language summary
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18-55
* Must be in good health with no significant medical history
* Clinical laboratory values within normal range or \< 1.2 times ULN
* BMI 18-32 (inclusive)
* Contraceptive use by men or women consistent with local regulations
* Able and willing to provide written informed consent
Exclusion Criteria:
* Any physical or psychological condition that prohibits study completion
* Known cardiac disease
* Active or history of malignancy in the past 5 years
* Serious infection within 1 month of screening
* Acute illness within 30 days of Day 1
* Surgery, bone fracture, or major musculoskeletal injury in the past 3 months
* History of suicidal behavior or suicidal ideation
* Active cigarette smokers and users of nicotine-containing products
* HIV, hepatitis B and hepatitis C positive
* SBP \>140 or \<90
* DBP \>90 or \<40
* HR \<40 or \>100
* QTcF \>450ms, cardiac arrhythmia, or clinically significant abnormal ECG
* Prescriptions, over-the-counter, or herbal medication within 7 days
* Vaccines within 14 days
* Other investigational products within 30 days
* Blood donation within 30 days
* Plasma donation within 7 days
* Pregnant or breastfeeding
* Otherwise unfit, on metabolic-altering lifestyle/diet, positive urine drug screen or intake of alcohol or caffeine-containing products
ALS Cohort Inclusion Criteria:
* Age 18-80
* ALS TRICALS risk score
* Stable dose of standard of care treatment
* Contraception use by men or women consistent with local regu…
What they're measuring
1
Safety and tolerability in healthy volunteers (SAD cohort)
Timeframe: 7 days
2
Safety and tolerability in healthy volunteers (SAD food effect cohort)
Timeframe: 15 days
3
Safety and tolerability in healthy volunteers (MAD cohort)